These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18991236)

  • 21. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
    Grant P; Lougee L; Hirschtritt M; Swedo SE
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):761-7. PubMed ID: 18315448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series.
    Di Nicola M; Tedeschi D; Martinotti G; De Vita O; Monetta M; Pozzi G; Janiri L
    J Clin Psychopharmacol; 2011 Oct; 31(5):675-7. PubMed ID: 21881460
    [No Abstract]   [Full Text] [Related]  

  • 23. Topiramate may induce obsessive-compulsive disorder.
    Thuile J; Even C; Guelfi JD
    Psychiatry Clin Neurosci; 2006 Jun; 60(3):394. PubMed ID: 16732760
    [No Abstract]   [Full Text] [Related]  

  • 24. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial.
    McElroy SL; Arnold LM; Shapira NA; Keck PE; Rosenthal NR; Karim MR; Kamin M; Hudson JI
    Am J Psychiatry; 2003 Feb; 160(2):255-61. PubMed ID: 12562571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
    Pekrul SR; Fitzgerald KD
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):593-5. PubMed ID: 26258664
    [No Abstract]   [Full Text] [Related]  

  • 26. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
    Bernhardt EB; Walsh KH; Posey DJ; McDougle CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):673-5. PubMed ID: 21881459
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of topiramate as an adjunctive medication in an elderly patient with treatment-resistant bipolar disorder.
    Madhusoodanan S; Bogunovic O; Brenner R; Gupta S
    Am J Geriatr Psychiatry; 2002; 10(6):759. PubMed ID: 12427586
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
    Yazici KU; Percinel I
    J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963
    [No Abstract]   [Full Text] [Related]  

  • 29. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up.
    Pittenger C; Kelmendi B; Wasylink S; Bloch MH; Coric V
    J Clin Psychopharmacol; 2008 Jun; 28(3):363-7. PubMed ID: 18480706
    [No Abstract]   [Full Text] [Related]  

  • 30. Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.
    Rodriguez CI; Lapidus KAB; Zwerling J; Levinson A; Mahnke A; Steinman SA; Kalanthroff E; Simpson HB
    J Clin Psychiatry; 2017 Apr; 78(4):466-467. PubMed ID: 28448699
    [No Abstract]   [Full Text] [Related]  

  • 31. Topiramate for the treatment of kleptomania: a case series and review of the literature.
    Dannon PN
    Clin Neuropharmacol; 2003; 26(1):1-4. PubMed ID: 12567156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topiramate-antagonism of L-glutamate-induced paroxysms in planarians.
    Raffa RB; Finno KE; Tallarida CS; Rawls SM
    Eur J Pharmacol; 2010 Dec; 649(1-3):150-3. PubMed ID: 20863783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
    Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.
    Pauls DL; Abramovitch A; Rauch SL; Geller DA
    Nat Rev Neurosci; 2014 Jun; 15(6):410-24. PubMed ID: 24840803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial.
    Mohammadianinejad SE; Abbasi V; Sajedi SA; Majdinasab N; Abdollahi F; Hajmanouchehri R; Faraji A
    Clin Neuropharmacol; 2011; 34(4):174-7. PubMed ID: 21738025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder.
    Oztürk M; Coskun M
    J Clin Psychopharmacol; 2009 Dec; 29(6):607-9. PubMed ID: 19910732
    [No Abstract]   [Full Text] [Related]  

  • 38. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
    Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
    Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inositol treatment of obsessive-compulsive disorder.
    Fux M; Levine J; Aviv A; Belmaker RH
    Am J Psychiatry; 1996 Sep; 153(9):1219-21. PubMed ID: 8780431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
    Vlček P; Polák J; Brunovský M; Horáček J
    Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.